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607Abstracts
intervention. Metformin and acarbose respectively reduce
cases of diabetes by 52 and 74 and reduce costs by $999
and $897 per patient. Acarbose is more effective than
metformin with slightly higher costs and an incremental
cost per life year gained of $1798. An aggressive lifestyle
modiﬁcation program is most effective, but is the most
costly intervention, generating incremental costs com-
pared to no treatment and with an incremental cost of
$9988 per life year gained relative to acarbose. Results
are most sensitive to effectiveness estimates for the inter-
ventions. CONCLUSIONS: These results suggest that the
use of acarbose, metformin, or lifestyle modiﬁcation to
prevent diabetes in people with IGT is cost-effective and
can even lead to cost savings. If an aggressive lifestyle
modiﬁcation can be implemented, it is most effective, but
increases costs by over $1000 per patient relative to
medical therapy. Acarbose is the better option if medica-
tion is used.
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OBJECTIVE: We examined cardiovascular risk by com-
paring pioglitazone (PIO) therapy with insulin (INS)
therapy in a large database in which medical, drug, and
laboratory information was collected using electronic
case report forms. METHODS: Adult patients with type
2 diabetes mellitus were included if active in the database
after 1999, and if no cardiovascular events were present
in the history before baseline. Patients on monotherapy
(PIO or INS) or in combination with sulfonylureas were
included. To avoid selection bias and increase precision
on the estimated treatment effect, we used propensity
scoring, stratiﬁed matching methods, and logistic regres-
sion analysis. Baseline demographics and clinical charac-
teristics such as disease duration, comorbidities, medical
therapies, and treatment duration were used to calculate
the propensity score. RESULTS: A total of 515 patients
taking PIO alone or with sulfonylureas were compared
with 2554 patients taking INS alone or in combination
with sulfonylureas. The treatment period ranged from
6–36 months. The crude cardiac event rate in the PIO
group was 5.44%, compared with 10.96% in the INS
group (P < 0.003), and the hazard ratio was 0.499 for
PIO (95% conﬁdence interval [CI]: 0.315, 0.791; P <
0.003). When patients on monotherapy alone were com-
pared, the crude event rates were 3.86%, compared with
11.32% in the INS group (P < 0.002), and the hazard
ratio was 0.346 for PIO (95% CI: 0.172, 0.694; P <
0.003). The signiﬁcant risk reduction in the PIO groups
could not be explained by baseline clinical or labora-
tory measurements. CONCLUSION: In a retrospective
propensity-matched cohort analysis in patients with type
2 diabetes, patients taking PIO had a signiﬁcantly lower
hazard for a cardiovascular event over a period of 6–36
months than those taking insulin.
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OBJECTIVES: Guidelines in Germany recommend use 
of Rosiglitazone in combination with Metformin for 
treatment of overweight and obese patients (BMI ≥ 25)
with Type 2 diabetes when Metformin monotherapy is 
no longer effective in maintaining glycaemic control. We
assess the cost-effectiveness of this strategy compared to
combination therapy with Glibenclamide. METHODS:
DiDACT, an established long-term economic model of
Type 2 diabetes, was adapted for clinical practice and
health care ﬁnancing rules in Germany. The model was
calibrated using CODE-2 study data and national statis-
tics. The perspective is that of the sickness funds, 
and includes all hospital care, physician consultations, 
medications, rehabilitation, physiotherapy, foot care and
sick leave. The model was used to simulate treatment 
histories for a mixed incident cohort of 1000 overweight
preobese patients (mean BMI = 26). Following failure 
of glycaemic control with Metformin alone, combination
therapy adding Rosiglitazone was compared to adding
Glibenclamide. The threshold for switching therapies was
7% HbA1c. In line with national guidelines, costs were
discounted at 5%. RESULTS: The model predicts that
adding Rosiglitazone (4mg titrated to 8mg daily) to 
Metformin produces better glycaemic control in most
patients, and extends viability of combination therapy by
8.5 years before requiring insulin. This is projected to gen-
erate 444 additional QALYs in a cohort of 1000 newly
diagnosed overweight patients over their lifetime. The
additional QALYs comprise 245 (55%) from better sur-
vival and 199 (45%) from delaying insulin and reduced
or delayed complications. Net cost increases are modest
since additional costs of Rosiglitazone are partly offset by
savings from delaying insulin therapy. After 20 years, 
the incremental cost-effectiveness ratio is €2730 per 
QALY gained (undiscounted) or €1804 (discounted).
CONCLUSIONS: Use of Rosiglitazone in combination
with Metformin to improve glycaemic control and delay
use of insulin in overweight patients is highly cost-
effective in Germany when compared to Metformin +
Glibenclamide.
